Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical R&D. According to the Baden-Württemberg Ministry of Economics, Labour and Housing, Baden-Württemberg is Europe's leading location for producing and distributing medicines for special therapies such as homeopathy as well as herbal ingredients.
The pharmaceutical industry continues to be a recession-proof employer and is very loyal to Baden-Württemberg. According to BIOPRO 127 pharmaceutical companies are located in Baden-Württemberg. Of them, 40 companies are pure distributors or suppliers. 87 of the 127 pharmaceutical companies carry out research, development and/or manufacture in Baden-Württemberg. The Baden-Württemberg Statistics Office has been able to acquire key figures for 2017 for 84 out of the 87 companies:
Most pharmaceutical companies are located in the southern Upper Rhine and Hochrhein-Bodensee regions (15 each) and the central Upper Rhine region (14).
Danube-Iller and Rhine-Neckar are the two regions with the highest revenues. Companies in the Donau-Iller region generated 30% of overall revenues and companies in the Rhine-Neckar region 17%.
Biotechnology is an important driver of innovation in the pharmaceutical industry. According to surveys by BIOPRO Baden-Württemberg, a total of 256 Baden-Württemberg companies are active in research, development and/or production in the region’s biotechnology and/or pharmaceutical industries. In 2017, 40,157 employees generated 11.2 billion euros in taxable revenues.